U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07103655) titled 'The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction' on July 29.
Brief Summary: This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.
Study Start Date: Jan. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Hypertrophic Cardiomyopathy (HCM)
Intervention:
DRUG: mavacamten
Add Mavacamten to guideline-directed ...